Contemporary Updates on the Physiology of Glucagon like Peptide-1 and Its Agonist to Treat Type 2 Diabetes Mellitus
Pathogenesis of diabetes mellitus involves scores of different factors, out of which Glucagon like factor-1 (GLP-1) plays a foremost role. GLP-1 is a peptide-hormone of the incretin system. It exhibits glucagonostatic as well as glucose dependent insulinotropic action. GLP-1 augments regeneration of β-cell, boost secretion of insulin and trim down weight gain in type-2 diabetes. GLP-1 discharge from the L cells of intestine is mediated by neural and hormonal factors which are stimulated by the occurrence of nutrients in the gastrointestinal tract. Conversely, GLP-1 is instantaneously shattered by enzyme dipeptidyl peptidase-IV. GLP-1 is also cleared by renal clearance. Diminished GLP-1 leads to attenuated insulin release leading to type-2 diabetes. Substitution of GLP-1 regularizes the insulin release and prevents type-2 diabetes. However, GLP-1 holding infinitesimal plasma half life limits its therapeutic effects. To surmount the limitations of indigenous GLP-1, several GLP-1 receptor agonist like Exenatide are been developed. Modifications in pharmaceutical formulation are also been made to meet the patients adherence to the medication of GLP-1 agonist.
KeywordsIncretin GLP-1 GLP-1 agonist Incretin mimetics Diabetes mellitus Insulin Hypoglycaemia
Authors like to acknowledge the dean and the management of College of Pharmaceutical Sciences, Dayananda Sagar University, Bangalore for their constant support to fulfil this work.
This project was self funded and received no grant from any outside agency.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with any animals or human participants performed by any of the authors.
- Ahrén B (2004) Sensory nerves contribute to insulin secretion by glucagonlike peptide-1 in mice. Am J Physiol 286:R269–R272Google Scholar
- Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004) A recombinant human glucagonlike peptide (GLP)-1–albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor–dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53(9):2492–2500CrossRefPubMedGoogle Scholar
- Balkan B, Li X (2000) Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol 279:R1449–R1454Google Scholar
- DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P (2011) Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 13(11):1145–1154CrossRefPubMedPubMedCentralGoogle Scholar
- Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA (2016) Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4(12):1004–1016CrossRefPubMedPubMedCentralGoogle Scholar
- Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomgarden Z, Bush M, Dagogo-Jack S, Davidson M, Einhorn D, Garvey W, Grunberger G (2013) American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 19(Supplement 2):1–48CrossRefGoogle Scholar
- Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55(6):1577–1596CrossRefPubMedGoogle Scholar
- Leech CA, Chepurny OG, Holz GG (2010) Epac2-dependent rap1 activation and the control of islet insulin secretion by glucagon-like peptide-1. In: Litwack G (ed) Vitamins & hormones. Academic Press, Cambridge, pp 279–302Google Scholar
- Ma X, Hui H, Liu Z, He G, Hu J, Meng J, Guan L, Luo X (2009) Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation. Diabetes Obes Metab 11(10):953–965CrossRefPubMedGoogle Scholar
- Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thøgersen H, Wilken M, Johansen NL (2007) Structure-activity and protraction relationship of long-acting glucagon- like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem 50(24):6126–6132CrossRefPubMedGoogle Scholar
- Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W (1993a) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76(4):912–917PubMedGoogle Scholar
- Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993b) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Investig 91(1):301–307CrossRefPubMedGoogle Scholar
- Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB (2008) The molecular basis for the delayed absorption of the once-daily human GLP-1 analoge, Liraglutide. Diabetes 57:A164–A164Google Scholar